In a 2 year longitudinal fingolimod study, we investigated the evolution of white matter integrity in the brain of relapsing-remitting multiple sclerosis (RRMS) patients under fingolimod treatment. Based on dMRI metrics from HARDI scans and statistical analysis, we found that MS patients experience a continued decline in white matter integrity during the first year of treatment with fingolimod with stabilization during the second year. Without a control group, it is unclear if these trends reflect on the impact of a treatment on disease progression.
This abstract and the presentation materials are available to members only; a login is required.